{
    "nct_id": "NCT03441555",
    "official_title": "Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "inclusion_criteria": "* Must have adequate coagulation, hematology, kidney, and liver function, per protocol.\n* Diagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML)\n* Meet the following disease activity criteria:\n* an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and\n* an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* If male participant is sexually active, he must agree from day 1 through 6 months after the last dose of alvocidib or 90 days after the last dose of venetoclax, whichever is longer, to practice the protocol-specified protection.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.\n* Prior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.\n* History of previous enrollment in Studies NCT02993523 or NCT03069352.\n* History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9) inhibitor.\n* History of Tumor Lysis Syndrome (TLS) due to previous exposure to venetoclax.",
    "miscellaneous_criteria": ""
}